Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 18, Issue 11, 2012, Pages 2034-2042

  Shahidi, Neal ^a   Fu, Yi Tzu Nancy ^a   Qian, Hong ^a   Bressler, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

immunosuppressive therapy; inflammatory bowel disease; interferon gamma release assay; tuberculin skin test; tuberculosis

Indexed keywords

TUMOR NECROSIS FACTOR ANTIBODY;

EMBASE; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SYSTEMATIC REVIEW; TUBERCULIN TEST;

HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; REVIEW LITERATURE AS TOPIC;

EID: 84867571869     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22901     Document Type: Review

References (57)

1. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in th United States and other Western countries: a systematic review. Curr Med Res Opin. 2008; 24: 319-328.
2. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. Occup Environ Med. 2008; 50: 1261-1272.
3. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135: 1907-1913.
4. Van Langerberg DR, Simon SB, Holtmann GJ, et al. The burden of inpatient costs in inflammatory bowel disease and opportunities to optimize care: a single metropolitan Australian center experience. J Crohns Colitis. 2010; 4: 413-421.
5. Loftus EV,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126; 1504-1517.
6. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644.
7. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462.
8. Kornbluth A, Sachar DB,. Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105: 501.
9. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104: 465.
10. Sadowski DC, Berstein CN, Bitton A, et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in Crohn's disease. Can J Gastroenterol. 2009; 23: 185-202.
11. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006; 55 (Suppl. 1): i16-35.
12. Cosnes J, Nion-Larmurier I, Beaugeri L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-241.
13. Rutgeerts P, Van Assche G, Vermiere S,. Review article: infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther. 2006; 23: 451-463.
14. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008; 134: 929-936.
15. Keane J,., Gershon S,., Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. N Engl J Med. 2001; 345: 1098-1104.
16. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis wth tumor necrosis alpha inhibitors may predispose to significant increase in tuberculosis risk: a multi-center-active-surveillance report. Arthritis Rheum. 2003; 48: 2122-2127.
17. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009; 3: 47-91.
18. Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumor necrosis factor antagonist therapies: a TBNET consensus statement. Eur Resp J. 2010; 36: 1185-1206.
19. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database System Rev. 2010; 1: CD000171.
20. Huebner RE, Schein MF, Bass JB Jr,. The tuberculin skin test. Clin Infect Dis. 1993; 17: 968-975.
21. Menzies D,. Interpretation of repeated tuberculin tests. Boosting, conversion and reversion. Am J Respir Crit Care Med. 1999; 159: 15-21.
22. Pai M, Riley LW,., Colford JM Jr, et al. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004; 4: 761-766.
23. Mow WS, Abreu-Martin MT, Papdakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limited the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004; 2: 309-313.
24. Pouchot J, Grasland A, Collet C, et al. Reliability of tuberculin skin test measurement. Ann Intern Med. 1997; 126: 210-214.
25. Jasmer RM, Nahid P, Hopewell PC,. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002; 347: 1860-1866.
26. Lalvani A,. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest. 2007; 131: 1898-1906.
27. Diel R, Lodenkamper R, Nienhaus A,. Evidence based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010; 137: 952-968.
28. Menzies D, Pai M, Comstock G,. Meta-analysis: new tests for diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007; 146: 340-354.
29. Sadatsafavi M, Shahidi N, Marra F, et al. A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy. J Clin Epidemiol. 2010; 63: 257-269.
30. Cattamanchi A, Smith S, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in hiv-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011; 56: 230-238.
31. Feinstein AR, Cicchetti DV,. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol. 1990; 43: 543-549.
32. Whiting P, Rutjes AWS, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003; 3: 25.
33. Sweeting MJ, Suttan AJ,., Lambert PC,. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004; 23: 1351-1375.
34. Higgins JPT, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2. 2002; 1539-1558.
35. Arias M, De Francisco R, Riestra S, et al. Performance of two interferon-gamma release assays (T-SPOT.TB and QuantiFERON-TB Gold in Tube) increase diagnostic yield of tuberculin skin testing for detection of latent tuberculosis in patients with inflammatory bowel disease. Gastroenterology. 2011; 140 (Suppl 1): S691.
36. Ministro P, Machado J, Arajo R, et al. Diagnosis of latent tuberculosis in patients with inflammatory bowel disease: Prospective comparison between tuberculin skin test and Interferon Gamma Release Assay (IGRA) test. Gastroenterology. 2011; 140 (Suppl 1): S776.
37. Papay P, Eser A, Winkler S, et al. Factors impacting the results of interferon-gamma release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2011; 17: 84-90.
38. Qumseya BJ, Ananthakrishnan AN, Skaros S, et al. QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis. 2011; 17: 77-83.
39. Guidi L, Andrisani G, Papa A, et al. Screening inflammatory bowel disease patients for latent tuberculosis in Italy: comparison of QuantiFERON-TB Gold versus tuberculin skin test. Gastroenterology. 2010; 138 (Suppl 1): S526.
40. Belard E, Semb S, Ruhwald M, et al. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. 2011; 17: 2340-2349.
41. Del Tedesco E, Oussalah A, Laharie D, et al. Interferon gamma release assay (Igra) and/or tuberculin skin test (Tst) in inflammatory bowel disease population: discordance and performance. Best strategy for detecting tuberculosis. Gastroenterology. 2010; 138 (Suppl 1): S673.
42. Greveson K, Murray C, Toumpanakis C, et al. Screening patients initiating Anti-TNF agents for mycobacterial infection using interferon-gamma release assays (IGRA): the experience of a large inflammatory bowel disease service. Gastroenterology. 2010; 138 (Suppl 1): S526.
43. Schoepfer AM, Flogerzi B, Fallegger S, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 2799-2806.
44. Ferebee SH,. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970; 26: 28-106.
45. Smith R, Cattamanchi A, Steingart KR, et al. Interferongamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol. 2011; 23: 377-384.
46. Choi JC, Shin JW, Kim JY, et al. The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection. Chest. 2008; 133: 1415.
47. Hotta K, Ogura T, Nishii K, et al. Whole blood interferon-gamma assay for baseline tuberculosis screening among Japenese healthcare students. PLoS One. 2007; 2: e803.
48. Kang YA, Lee HW, Yoon HI, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA. 2005; 293: 2756-2761.
49. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-gamma assays for the diagnosis of Mycobacterium tuberculosis infection. Eur Respir J. 2006; 28: 24-30.
50. Centers for Disease Control and Prevention. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis Infection-United States, 2010. MMWR. 2010; 59: 1-25.
51. Canadian Tuberculosis Committee. Recommendations on interferon gamma release assays for diagnosis of latent tuberculosis infection-2010 update. CDDR. 2010; 36: 1-25.
52. Swiss Lung Association. Handbuch Tuberkulose 2011 (Handbook Tuberculosis 2011), preliminary version. Available at: http://www.tbinfo.ch/de/publikationen/ handbuch-tuberkulose.html; 2011.
53. Kucharz EJ, Korzeniewska-Kosela M, Kotulska A,. Recommendations for prophylaxis and management of tuberculosis in patients treated with TNF-alpha antagonists. Reumatologia. 2008; 46: 51-54.
54. HPA Tuberculosis Programme Board. Health Protection Agency position statement on the use of interferon gamma release assay (IGRA) test for tuberculosis (TB). London: Health Protection Agency; 2008. p 1-12.
55. Al Jahdali HH, Baharoon S, Abba AA, et al. Saudi guidelines for testing and treatment of latent tuberculosis infection. Ann Saudi Med. 2010; 30: 38-49.
56. Wang L, Turner MO, Elwood RK, et al. A meta-analysis on the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax. 2002; 57; 804-809.
57. Marra F, Marra CA, Sadatsafavi M, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis. 2008; 1: 1414-1424.